for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Endo International PLC

ENDP.O

Latest Trade

5.60USD

Change

-0.24(-4.11%)

Volume

8,146,284

Today's Range

5.51

 - 

5.94

52 Week Range

1.94

 - 

10.89

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.84
Open
5.79
Volume
8,146,284
3M AVG Volume
227.17
Today's High
5.94
Today's Low
5.51
52 Week High
10.89
52 Week Low
1.94
Shares Out (MIL)
233.67
Market Cap (MIL)
1,364.64
Forward P/E
2.06
Dividend (Yield %)
--

Next Event

Q4 2021 Endo International PLC Earnings Release

Latest Developments

More

Endo Posts Q3 Revenue Of $772 Million

Endo International PLC sAYS California State Court Issues Tentative Ruling In Endo's Favor Following Opioid Trial

Endo Comments On Non-Infringement Ruling In VASOSTRICT Patent Litigation

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Endo International PLC

Endo International plc is a generics and specialty branded pharmaceutical company. The Company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals and International Pharmaceuticals. It has a portfolio of branded pharmaceuticals offered by its U.S. Branded Pharmaceuticals segment that includes brand names, such as Lidoderm, OPANA ER, Voltaren Gel, Percocet, Fortesta Gel, Testim, TESTOPEL, Aveed, Supprelin LA and XIAFLEX. Its non-branded U.S. Generic Pharmaceuticals portfolio consists of products, such as tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics and patches. The Company's generics portfolio has a range of dosage forms and delivery systems. The International Pharmaceuticals segment includes various specialty pharmaceutical products for the Canadian, Latin American and world markets.

Industry

Biotechnology & Drugs

Contact Info

Minerva House, Simmonscourt Road

000 00

Ireland

+353.1.2682000

http://www.endo.com

Executive Leadership

Mark G. Barberio

Independent Non-Executive Chairman of the Board

Blaise Coleman

President, Chief Executive Officer, Director

Mark Bradley

Chief Financial Officer, Executive Vice President

Patrick Barry

Executive Vice President and Chief Commercial Officer, U.S. Branded Business

Matthew Joseph Maletta

Executive Vice President, Chief Legal Officer

Key Stats

3.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

2.9K

2019

2.9K

2020

2.9K

2021(E)

2.9K
EPS (USD)

2018

2.890

2019

2.380

2020

2.870

2021(E)

2.833
Price To Earnings (TTM)
194,666.70
Price To Sales (TTM)
0.46
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
2.86
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-0.01
Return on Equity (TTM)
-0.01

Latest News

Latest News

Arnold & Porter withdraws from opioid cases after sanctions rec

Arnold & Porter Kaye Scholer is withdrawing from representing drugmaker Endo International Plc in litigation over the opioid epidemic, two weeks after a referee appointed by a New York state judge recommended that the firm be sanctioned for failing to turn over evidence...

Alabama settles opioid claims against Endo, in talks with McKesson

Alabama has resolved claims against drugmaker Endo International Plc over its alleged role in the opioid epidemic and is in settlement talks with distributor McKesson Corp, putting on hold a trial of the state's case against the two companies that was set to begin Monday.

McKesson, Endo face multi-billion dollar opioid trial in Alabama

Alabama is set to take drug distributor McKesson Corp and pharmaceuticals maker Endo International Plc to trial over claims they fueled the opioid epidemic as the state fights for a multi-billion dollar payout after rejecting a nationwide settlement.

Referee recommends sanction for Arnold & Porter in N.Y. opioid case

A court-appointed referee recommended that Arnold & Porter Kaye Scholer be sanctioned for failing to disclose evidence in a timely manner to the state of New York and two counties, which had accused its client Endo International Plc of fueling the U.S. opioid epidemic.

Special master to consider default against Endo in opioid trial

A New York judge has appointed a special master to advise him on whether to impose default judgment or contempt against drugmaker Endo International Plc for withholding evidence in a trial over its role in the opioid epidemic.

Endo now faces contempt as well as default in N.Y. opioid trial

Endo International PLC, already facing potential default judgment for late production of evidence in New York's lawsuit against it over its opioid marketing, could also be held in contempt for violating a separate discovery order.

Endo, Arnold & Porter deny deliberately withholding opioid evidence

Endo International PLC and its law firm Arnold & Porter Kaye Scholer have denied willfully withholding evidence from New York and two counties accusing the company of fueling an opioid epidemic, urging a judge to deny the state's motion for default judgment.

Endo faces default over hiding 'smoking gun' opioid evidence (again)

A New York judge has ordered Endo International PLC and its law firm Arnold & Porter Kaye Scholer to show cause why he should not enter default judgment that the drugmaker is liable for fueling an opioid epidemic, after the state accused it of withholding damning evidence.

Drugmaker Endo settles opioid claims by Tennessee counties, cities for $35 million

Endo International Plc has agreed to pay $35 million to settle a lawsuit by Tennessee local governments and on behalf of a child allegedly born addicted to painkillers accusing the drugmaker of fueling the opioid epidemic, the company announced Thursday.

Drugmaker Endo settles opioid claims by Tennessee counties, cities for $35 million

Endo International Plc has agreed to pay $35 million to settle a lawsuit by Tennessee local governments and on behalf of a child allegedly born addicted to painkillers accusing the drugmaker of fueling the opioid epidemic, the company announced Thursday.

5th Circuit upholds FTC ruling against Impax, Endo in reverse-payment case

A federal appeals court has upheld the Federal Trade Commission's finding that Impax Laboratories LLC entered into an illegal settlement that delayed the release of a generic version of Endo International Plc's opioid Opana ER.

July trial date set for Tenn. counties' $2.4 bln damages claims against Endo

A Tennessee judge on Thursday set a July 26 trial date for a group of Tennessee counties' claim seeking $2.4 billion in damages from Endo International PLC over its alleged role in the opioid epidemic, two days after entering default judgment of liability against the company...

Endo starts manufacturing Novavax's potential COVID-19 vaccine

Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.

New York charges Johnson & Johnson with insurance fraud over opioid claims

New York state filed civil charges on Thursday accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to elderly patients.

BRIEF-U.S. FDA Approves Qwo™ (Collagenase Clostridium Histolyticum-Aaes), The First Injectable Treatment For Cellulite

* U.S. FDA APPROVES QWO™ (COLLAGENASE CLOSTRIDIUM HISTOLYTICUM-AAES), THE FIRST INJECTABLE TREATMENT FOR CELLULITE

BRIEF-Endo International Announces Final Tender Results Of Previously Announced Exchange Offers And Consent Solicitations

* ENDO INTERNATIONAL PLC ANNOUNCES FINAL TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED EXCHANGE OFFERS AND CONSENT SOLICITATIONS

BRIEF-Endo International Announces Final Tender Results Of Its Previously Announced Exchange Offers And Consent Solicitations

* ENDO INTERNATIONAL PLC ANNOUNCES FINAL TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED EXCHANGE OFFERS AND CONSENT SOLICITATIONS

New York charges Endo with insurance fraud over opioid claims

New York state filed civil charges on Wednesday accusing Endo International Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs, adding fuel to the nation's opioid crisis.

New York charges Endo with insurance fraud over opioid claims

New York state filed civil charges on Wednesday accusing Endo International Plc of insurance fraud for misrepresenting the safety and efficacy of its opioid drugs.

BRIEF-Endo International PLC Announces Proposed Exchange Offers And Consent Solicitations

* ENDO INTERNATIONAL PLC ANNOUNCES PROPOSED EXCHANGE OFFERS AND CONSENT SOLICITATIONS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up